复宏汉霖(02696.HK)HLX02注射用曲妥珠单抗欧盟首个订单出厂
复宏汉霖(02696.HK)宣布,HLX02(注射用曲妥珠单抗)首个欧盟订单产品在公司徐汇生产基地顺利完成出库前最後检测及装箱工作,即将踏入欧洲市场。
据悉,出厂的产品为HLX02在欧盟的首个订单,本批产品将通过冷链运输空运至商业合作夥伴Accord Healthcare Limited於英国的生产基地,预计可於当地时间7月2日抵达英国,正式进入Accord生产基地仓库。
HLX02是由复宏汉霖按照欧盟和中国生物类似药相关法规自主开发和生产的生物类似药,其欧盟MAA(Marketing Authorisation Application, 营销授权申请)由复宏汉霖与Accord共同推动,未来HLX02在欧洲的商业化将由Accord负责。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.